Background: The primary aim of the study was to investigate prognosis and long-term survival in young breast cancer patients with a BRCA1 or BRCA2 germline mutation compared with noncarriers. The secondary aim was to investigate whether differences in survival originate from associations with tumor characteristics, second cancers, and/or treatment response. Methods: We established a cohort of invasive breast cancer patients diagnosed younger than age 50 years in 10 Dutch hospitals between 1970 and 2003. BRCA1/2 testing of most prevalent mutations was mainly done using DNA isolate from formalin-fixed paraffin-embedded nontumor tissue. Survival estimates were derived using Cox regression and competing risk models. Results: In 6478 breast cancer patients, we identified 3.2% BRCA1 and 1.2% BRCA2 mutation carriers. BRCA1 mutation carriers had a worse overall survival independent of clinico-pathological/treatment characteristics, compared with noncarriers (adjusted hazard ratio [HR] ¼ 1.20, 95% confidence interval [CI] ¼ 0.97 to 1.47), though only statistically significant in the first five years of follow-up (adjusted HR ¼ 1.40, 95% CI ¼ 1.07 to 1.84). A large part of the worse survival was explained by incidence of ovarian cancers. Breast cancer-specific, disease-free, and metastasis-free survival results were less pronounced and mostly statistically nonsignificant but in the same direction with those of overall survival. Overall survival was worse, although not statistically significantly, within the ER-negative or ER-positive, grade 3, and small tumor subgroups. The worse survival was most pronounced in non-chemotherapy-treated patients (adjusted HR ¼ 1.54, 95% CI ¼ 1.08 to 2.19). Power for BRCA2 mutation carriers was limited; only after five years' follow-up overall survival was worse (adjusted HR ¼ 1.47, 95% CI ¼ 1.00 to 2.17). Conclusions: BRCA1/2 mutation carriers diagnosed with breast cancer before age 50 years are prone to a worse survival, which is partly explained by differences in tumor characteristics, treatment response, and second ovarian cancers.
BRCA1 and BRCA2 are high-risk breast cancer susceptibility genes, with 11-to 12-fold increased relative risks for women in the general population (1) . Though BRCA1/2 mutations are most prevalent in breast cancer families (10%-25%), a noteworthy prevalence of 3% to 5% carriers and more than 10% in triplenegative breast cancer have been reported from unselected hospital and population-based series (2, 3) . The reported risk estimates and the role of BRCA1/2 in the DNA damage response pathway led to speculations about the impact of germline mutations in these genes on breast cancer prognosis, reflected by reviews of mechanisms and prognostic studies (4) (5) (6) (7) (8) (9) (10) . A few small studies in the early years after discovery of the BRCA1/2 genes in 1994/1995 indicated that survival of BRCA1/2 mutation carriers may be worse (11, 12) .
In the last decades, many studies have been conducted to investigate the association between BRCA1/2 mutations and survival (13) . Challenged by the relatively low prevalence of the mutations, testing and survivor bias, and lack of adjustments for treatment and risk-reducing surgeries of breast and ovaries, the evidence for a worse survival of BRCA1/2 mutation carriers is still inconclusive (13) . Moreover, it is unclear to what extent worse survival can be explained by differences in tumor characteristics, treatment, and/or other differences between carriers and noncarriers. For example, BRCA1-associated breast cancers are more often estrogen receptor (ER) negative and high grade (14, 15) . Some studies showed a differential response of BRCA1/2 mutation carriers to chemotherapy (16, 17) and PARP inhibitors (18) . In addition, BRCA1/2 mutation carriers are at risk of other primary tumors, such as ovarian cancer (19, 20) .
In general, young breast cancer patients, especially those younger than age 40 years, have been shown to have worse survival compared with older patients (21, 22) . It is unclear whether this worse survival in young breast cancer patients is due to higher prevalence of BRCA1/2 mutation carriers in this group. These observations render the younger breast cancer population a more urgent and identifiable group to study BRCA1/2 prognosis. We aimed to investigate prognosis and long-term survival of BRCA1-and BRCA2-related breast cancer in patients diagnosed before age 50 years in a large hospital-based cohort with comprehensive clinico-pathological data. The secondary aim was to investigate whether differences in survival between carriers and noncarriers are due to associations with tumor characteristics and/or treatment response.
Methods

Patients
The study comprised an unselected, that is, nonfamily nor clinical genetic center-based, consecutive series of 7403 female patients with invasive breast cancer diagnosed before age 50 years without a previous cancer diagnosis (except for nonmelanoma skin tumors). Patients included in the study were treated for their primary breast cancer in 10 different centers throughout the Netherlands between 1970 and 2003. For details regarding patient inclusion and data collection, see Figure 1 and the Supplementary Methods (available online). To avoid survivor bias we mainly used formalin-fixed paraffinembedded normal (nontumor) tissue to isolate DNA; for 87.6% of total cohort, we were able to collect germline DNA of sufficient quality. In the overall survival analyses, we included 6478 patients. For part of the cohort, we were unable to retrieve information about cause of death or recurrences, leaving 3515 No follow-up (n excluded = 1)
No follow-up (n excluded = 6) SensiƟvity analysis in which paƟents with synchronous bilateral breast cancer and/or metastasis at or within three months aŌer diagnosis were excluded (n excluded = 174), leaving (n = 6304)
PaƟents with distant metastasis at or within three months aŌer diagnosis (n excluded = 75)
Included in the analysis of disease-and metastasis-free survival (n = 3440) 
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patients for breast cancer-specific survival and 3440 patients for disease-free and metastasis-free survival analyses. No written informed consent was required. The secondary use of longterm stored tissue samples and clinical data in this study was in accordance with Dutch legislation and codes of conduct (http://www.federa.org/codes-conduct) (23) and approved by the review boards of the participating institutions.
BRCA1/2 Mutation Testing
Most prevalent BRCA1/2 mutations were tested as described elsewhere (24 Schmidt MK, Cornelissen S, van de Broek AJ, et al. BRCA1 and BRCA2 germline mutations panel testing on FFPE-tissue: characterization of a hospital-based cohort of young breast cancer patients. Personal communication). In short, BRCA1/2 mutation analysis included testing for 92 variants representing approximately 61% of the BRCA1/2 mutations prevalent in families in the Netherlands using allelic discrimination or fragment length analyses; Sanger sequencing was used for confirmation of mutations. One patient sample, in which both a BRCA1 mutation and a BRCA2 mutation were detected, was added to the group of BRCA1 mutation carriers. Using a trusted third party and a coding procedure, the clinical data and BRCA1/2 mutation results were anonymized before linkage (25) .
Statistical Methods
For overall survival, an event was defined as death due to any cause. For breast cancer-specific survival, an event was defined as death due to breast cancer. For disease-free survival, any recurrence (local, regional, distant, but not including a second primary cancer) or death due to breast cancer, whatever came first, was defined as an event. For metastasis-free survival, a first distant metastasis or death due to breast cancer was defined as an event. Time at risk started at the diagnosis of the first breast cancer and ended at the date of diagnosis of the event of interest for the specific outcome, or date of most recent follow-up. Absolute overall survival estimates for BRCA1/2 mutation carriers and noncarriers were derived using Kaplan-Meier curves; for the other outcomes, absolute survival estimates were derived using cumulative incidence curves accounting for competing risks. The Fine and Gray method was used for univariate and multivariable competing risk regression analyses to determine the subdistribution hazard ratios (HRs) (26) . Deaths due to other causes than breast cancer were taken into account as competing events in all analyses except for overall survival; for the latter Cox regression models were used. See Supplementary Methods (available online) for covariates included and number of missing values (Supplementary Tables 1-2 , available online), which were imputed using multiple imputation by chained equations (R version 3.3.0, MICE package 2.25 [27, 28] ). Ipsilateral breast mastectomy and contralateral breast mastectomy (not as therapy for a second invasive breast cancer, in situ breast carcinoma, or local recurrence) were taken into account as time-varying covariates in the multivariable analyses. Oophorectomy was not taken into account because of indication bias and incomplete data about the reason of oophorectomy. Second breast cancer and ovarian cancer were taken into account as time-varying interaction terms with BRCA1/2 mutation status to determine the hazard ratio (HR) of the association between BRCA1/2 mutation status and survival before incidence of second breast and/or ovarian cancers. Subgroup analyses were performed using an interaction term with the BRCA1/2 mutation status.
The proportional hazard assumption was verified comparing log-minus-log and hazard curves with each other. For reason of nonproportionality and for reasons of clinical relevance, we performed additional analyses for the follow-up period within and after five years. See the Supplementary Methods (available online) for the different sensitivity analyses performed. All statistical tests were two-sided; a P value of less than .05 was considered statistically significant. The analyses were performed using STATA-11.0.
Results
Patient and Tumor Characteristics of BRCA1 and BRCA2 Mutation Carriers vs Noncarriers
Median follow-up of the included 6478 invasive breast cancer patients diagnosed before age 50 years was 14 years (descriptive data in Table 1 ; Supplementary Table 1-2, available online). We detected 3.2% BRCA1 and 1.2% BRCA2 mutation carriers. BRCA1/2 mutation carriers were younger at diagnosis compared with noncarriers; breast cancer treatment was similar except for a higher proportion of chemotherapy-treated patients among BRCA1 mutation carriers. BRCA1-related tumors were more often grade 3, ER negative, triple negative, medullary, and less often lobular. BRCA2-related tumors were more often grade 3 and lymph node positive. Median follow-up for patients who were alive at the end of followup was similar in carriers and noncarriers. Risk-reducing surgeries during follow-up after breast cancer diagnosis were more common in carriers (Table 1) .
Prognosis and Long-term Survival of BRCA1 and BRCA2 Mutation Carriers vs Noncarriers
BRCA1 and BRCA2 mutation carriers each had differential survival curves compared with noncarriers ( Figure 2 ; Supplementary Table 3, available online). An absolute 10-year overall survival difference of 10% was seen in BRCA1/2 mutation carriers (61.4% for BRCA1 and 60.9 for BRCA2) compared with noncarriers (70.4%). The results of the overall survival analyses are shown in Figure 3 and Supplementary Table 4 (available online), a full multivariable Cox regression model is shown in Table 2 . BRCA1 mutation carriers had a statistically significantly worse overall survival compared with noncarriers (HR ¼ 1.28, 95 % CI ¼ 1.05 to 1.57, P ¼.01), which was attenuated if adjusted for clinico-pathological and treatment information (adjusted HR ¼ 1.20, 95% CI ¼ 0.97 to 1.47, P ¼.09), but the worse survival was most apparent in the first five years after diagnosis (adjusted HR ¼ 1.40, 95% CI ¼ 1.07 to 1.84, P ¼.02) (Figure 3 ; Supplementary Table 4 , available online). BRCA2 mutation carriers had a worse overall survival (HR ¼ 1.26, 95% CI ¼ 0.91 to 1.73, P ¼.16), but this difference was only statistically significant after five years of follow-up (HR ¼ 1.56, 95% CI ¼ 1.06 to 2.28, P ¼.02). This worse survival, observed over the whole period, mostly disappeared after adjustment for clinico-pathological and treatment information (adjusted HR ¼ 1.06, 95% CI ¼ 0.77 to 1.47, P ¼.71) and was slightly attenuated after five years (adjusted HR ¼ 1.47, 95% CI ¼ 1.00 to 2.17, P ¼.05) (Figure 4 ; Supplementary Table 4 , available online). Results for breast cancer-specific, disease-free, and metastasis-free survival were mostly in the same direction with those for overall survival, but (strongly) attenuated and mostly not statistically significant (Figures 3 and 4 ; Supplementary Table 4, available online).
Sensitivity analyses for overall survival excluding either patients with synchronous bilateral breast tumors (more often occurring in carriers) (Table 1 ) or a distant metastasis at primary Table 5 , available online).
In the subgroup analyses of periods of diagnosis before and after 1995, that is, the year of start of BRCA1/2 mutation screening, the estimates after 1995 were attenuated and no effect of the BRCA1 and BRCA2 mutation status on survival was seen. The estimates derived for the period before 1995, which included most patients (4642 of 6478), became even more pronounced toward a worse survival (Supplementary Table 6 , available online). In the subgroup analyses of patients that were, none related to this study, referred or not to the Clinical Genetic Center for counseling and BRCA1/2 mutation testing, BRCA1 mutation carriers had a statistically significantly worse unadjusted overall survival compared with noncarriers only in the subgroup of nonreferred patients but no longer so after adjustment for clinico-pathological variables (Supplementary Figure 1 and Supplementary Table 7 , available online).
Analyses of Second Primary Breast or Ovarian Cancer and Risk-Reducing Surgeries
To understand the contribution of the higher incidence of second breast and ovarian tumors to the worse survival observed 
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in BRCA1/2 mutation carriers compared with noncarriers, we investigated their association with survival (Supplementary  Table 8 , available online). BRCA1 mutation carriers had a high incidence of ovarian cancer (68/10 000 years observed; noncarriers: 6/10 000 years observed). Within BRCA1 mutation and noncarriers, incidence of ovarian cancer was associated with worse survival, respectively (HR ¼ 3.12, 95% CI ¼ 1.70 to 5.70, P <.001; and HR ¼ 3.98, 95% CI ¼ 2.81 to 5.65, P <.001).
Considering the association of BRCA1 with overall survival before incidence of ovarian cancers (modeled using an interaction term), the hazard ratio was attenuated (HR ¼ 1.10, 95% CI ¼ 0.88 to 1.36, P ¼.42) compared with the hazard ratio taking into account also the follow-up after ovarian cancer incidence (HR ¼ 1.20, 95% CI ¼ 0.97 to 1.47, P ¼.09) (Supplementary Table 4 , available online), suggesting that part of the worse survival is explained by ovarian cancers during follow-up. Subsequent inclusion of information on a second breast cancer shifted the estimates back to a worse survival for BRCA1 mutation carriers (HR ¼ 1.21, 95% CI ¼ 0.96 to 1.53, P ¼.11) because of the differential effects of second breast cancers on survival in BRCA1 mutation compared with noncarriers ( Figure 3 ; Supplementary Table  4 and Supplementary Table 8 , available online).
The protective effect of a risk-reducing contralateral mastectomy during follow-up after diagnosis of breast cancer (2.8% in noncarriers after a median follow-up of 3.0 years, range ¼ 0.0-22.4 years; 20% in BRCA1 mutation carriers after 1.3 years, range ¼ 0.0-24.0 years) on overall survival was statistically significant in BRCA1 mutation carriers but not in noncarriers (Supplementary Table 8 , available online); for BRCA2 mutation carriers, there were not enough data to perform the analyses (four mastectomies among 75 BRCA2 mutation carriers [5.3%] after 2.8 years, range ¼ 0.3-3.9 years).
Survival of BRCA1 and BRCA2 Mutation Carriers vs Noncarriers in Tumor and Treatment Subgroups
To further disentangle the association between tumor characteristics and BRCA mutation status, subgroup analyses were performed stratifying by ER status of the primary breast tumor and only selecting high grade or small (<2 cm) tumors (Figure 3 ; Supplementary Tables 9-11, available online). Within both ERpositive and ER-negative tumors, BRCA1 and BRCA2 mutation carriers still had differential survival curves compared with Figure 2 . Cumulative overall survival (A), breast cancer-specific survival (B), disease-free survival (C), and metastasis-free survival (D) for BRCA1 mutation carriers, BRCA2 mutation carriers, and noncarriers. Absolute overall survival estimates were derived using Kaplan-Meier curves; for the other outcomes, absolute survival estimates were derived using cumulative incidence curves accounting for competing risks; (B-D) are based on the data set including breast cancer-specific follow-up data ( Figure 1 ): 2968 patients were excluded because of missing (sufficient) information regarding cause of death and recurrences; for disease-free and metastasis-free survival (C-D), 75 extra patients were excluded with metastasis at or within three months after diagnosis. Figure 2, available online) . The effect of BRCA1 mutation status on overall survival within the different ER subgroups was similar (Figure 3 ; Supplementary Table 9 , available online). However, a statistically significantly worse overall survival for BRCA2 mutation carriers was seen only within the ER-positive subgroup, again mostly after five years' follow-up (adjusted HR ¼ 2.04, 95% CI ¼ 1.22 to 3.39, P ¼.01) (Supplementary Table 9 , available online).
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Within grade 3 tumors, results were similar to results in the whole group, but mostly no longer statistically significant, except for BRCA2 mutation carriers after five years' follow-up (adjusted HR ¼ 1.95, 95% CI ¼ 1.12 to 3.40, P ¼.02) (Supplementary Table 11 , available online). For BRCA2 mutation carriers, a worse survival was found within the small tumors after five years' follow-up (Supplementary Table 11 , available online).
In subgroup analyses by chemotherapy treatment for the primary breast cancer, the effects of the BRCA1 and BRCA2 mutation status on overall survival within the distinct treatment subgroups were different (Supplementary Figure 2, available online) . The strongest statistically significantly worse survival was seen in BRCA1 mutation carriers who did not receive adjuvant chemotherapy treatment, even after adjustment for clinico-pathological characteristics (adjusted HR ¼ 1.54, 95% CI ¼ 1.08 to 2.19, P ¼.02); this worse survival was not seen in the treated subgroup (adjusted HR ¼ 1.05, 95% CI ¼ 0.79 to 1.41, P ¼.72) (Figure 3 ; Supplementary Table 12, available online). In contrast, the association of BRCA2 mutation status with survival tended to be worse in chemotherapy-treated patients, but again only statistically significantly so after five years' follow-up (Supplementary Table  12 , available online).
Discussion
In a hospital-based large cohort of young breast cancer patients, we found evidence for a worse survival in both BRCA1 and BRCA2 mutation carriers, but with different patterns. BRCA1 mutation carriers had relatively worse overall survival, in order of magnitude 1.2 to 1.4, which was mostly evident in the first five years, compared with noncarriers. This worse survival was specifically evident among patients who did not receive systemic-adjuvant treatment and remained statistically significant in small tumors. Statistical power for BRCA2 mutation carriers was limited and survival was not statistically significantly worse, except after five years' follow-up (including in subgroups of grade 3 tumors, ERpositive tumors, or systemic-treated patients).
Our findings are largely in line with previously published studies summarized in a comprehensive systematic review and two additional studies that were published since (13, 29, 30) , but now indicate different patterns for BRCA1 and BRCA2 and the likely underlying causes of these differences. BRCA1 mutation carriers, who are most likely to develop ER-or triple-negative tumors, respond better to chemotherapy, and after adjustment for tumor characteristics and treatment information, the worse survival observed in this group is attenuated. Furthermore, part of the worse survival seems to be attributable to the incidence of second primary ovarian tumors. This is also in line with reports of increased risk of ovarian cancer in BRCA1/2 muation carriers (20, 31) , long-term increased risk of subsequent ovarian cancer in breast cancer patients younger than age 50 years (32) , and the previously reported protective impact of oophorectomy after breast cancer on mortality (33). Forest plot of the results for overall survival and breast cancer-specific survival of BRCA1 mutation carriers compared with noncarriers in the whole cohort and for overall survival in subgroups based on tumor estrogen receptor status, grade, size, and systemic treatment. All patients, overall (hazard ratios from Cox regression models) and breast cancer-specific survival (hazard ratios from competing risk models using the Fine and Gray method): black bullet: unadjusted hazard ratio; grey bullet: hazard ratio adjusted for age at and calendar year of diagnosis, grade, size, nodal status, M-status, estrogen receptor status, chemotherapy, endocrine therapy, type of surgery (with and without radiotherapy), contralateral and ipsilateral breast mastectomy (both time-varying); light grey bullet: hazard ratio additionally adjusted for interaction of the BRCA1 mutation status with ovarian cancer (only for overall survival) and with second invasive breast cancer (both time-varying). Subgroups, overall survival (hazard ratios from Cox regression models): black bullet: hazard ratio adjusted for interaction of the BRCA1 mutation status with ovarian cancer and with second invasive breast cancer (both time-varying); light grey bullet: hazard ratio additionally adjusted for age at and calendar year of diagnosis, grade*, size*, nodal status, M-status, estrogen receptor status*, chemotherapy*, endocrine therapy, type of surgery (with and without radiotherapy), contralateral and ipsilateral breast mastectomy (both time-varying). *Excluded in specific subgroup analyses. Age and calendar year were included continuously; other variables were used categorically as indicated in Supplementary Table 1 (available online) . For breast cancer-specific survival, 2968 patients were excluded because of missing (sufficient) information regarding cause of death and recurrences (Figure 1 ). CI ¼ confidence interval; HR ¼ hazard ratio.
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For BRCA2 mutation carriers, who develop mostly ER-positive and in our study also more often high-grade tumors, the story is more complicated, partly due to lack of sufficient data (13) . ER-positive patients in this cohort specifically might have been treated somewhat suboptimally based on today's standard, though according to guidelines in those days, as less than 10% of patients received endocrine treatment. As shown by others, ER-positive patients diagnosed younger than age 50 years experienced a larger improvement of survival over time (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) ) compared with ER-negative patients, likely due to treatment advances with endocrine therapies (34) . However, this does not completely explain the delayed (after five years' follow-up) worse survival of BRCA2 mutation carriers compared with noncarriers seen in our study, which thus may at least partly be explained by highergrade and/or less chemotherapy-responsive ER-positive tumors, specifically because our patients were treated mostly with CMF-like regimens, which were standard of care in those years and for which clinical trial data indicate to be insufficient for young women particularly (35) . With new guidelines for wider application of and longer endocrine treatment nowadays (36), the outcome for BRCA2 mutation carriers may be different, but more recent prospective cohorts are needed to solve this question. Figure 4 . Forest plot of the results for overall survival and breast cancer-specific survival of BRCA2 mutation carriers compared with noncarriers in the whole cohort.
All patients, overall (hazard ratios from Cox regression models) and breast cancer-specific survival (hazard ratios from competing risk models using the Fine and Gray method): black bullet: unadjusted hazard ratio; grey bullet: hazard ratio adjusted for age at and calendar year of diagnosis, grade, size, nodal status, M-status, estrogen receptor status, chemotherapy, endocrine therapy, type of surgery (with and without radiotherapy), contralateral and ipsilateral breast mastectomy (both time-varying); light grey bullet: hazard ratio additionally adjusted for interaction of the BRCA2 mutation status with ovarian cancer (only for overall survival) and with second invasive breast cancer (both time-varying). Age and calendar year were included continuously; other variables were used categorically as indicated in Supplementary   Table 1 (available online) . For breast cancer-specific survival, 2968 patients were excluded because of missing (sufficient) information regarding cause of death and recurrences ( Figure 1 ). CI ¼ confidence interval; HR ¼ hazard ratio.
BRCA1/2 mutation carriers in our study that were not referred to the Clinical Genetic Center and those diagnosed before 1995 had the most pronounced worse survival compared with noncarriers in unadjusted analyses. This could partially be explained by survivor bias for referral to the Clinical Genetic Center and/or due to different treatment or preventive surgery decisions related to family history and/or knowledge of BRCA1/2 mutation carriership (37) . However, our design and comprehensive data allowed us to adjust sufficiently for these factors in the multivariable analyses, showing no remaining differences between referred and nonreferred patients.
Though BRCA1/2 mutation carriers are at increased risk of developing a contralateral breast cancer (24) and tamoxifen treatment has been shown to be protective (38), we found no evidence for worse survival attributable to second primary breast cancer within BRCA1/2 mutation carriers. However, in a previous paper we showed that a large part (70% of those diagnosed after 1995) of the mutation carriers in our cohort were later counseled and tested for BRCA1/2 mutations at clinical genetic centers (2); more intensive surveillance, but also treatment of the second breast cancer, might be expected. Unfortunately, we lack information about characteristics and treatment of the second primary breast cancers.
We did observe a protective effect of risk-reducing contralateral mastectomy in BRCA1 mutation carriers and not in noncarriers on mortality risk, but our study had limited power for these subgroup analyses. In previous studies reporting a lower mortality, especially in patients younger than age 40 years after contralateral risk-reducing mastectomy, results may at least partly be explained by survivor or selection bias (39, 40) .
The strengths of our study are the unbiased design; the large size of the cohort with comprehensive clinico-pathological data and follow-up including risk-reducing surgeries; the cohort being mostly a representation of a period of diagnosis in which patients were not aware of their BRCA1/2 mutation carriership, and therefore were less likely to have an affected choice of treatment; and the availability of BRCA1/2 genotypes of all patients (though representing a selection of most prevalent BRCA1/2 germline mutations). However, lack of complete coverage of the BRCA1/2 genes (due to working with degraded formalin-fixed paraffin-embedded derived DNA), which might have attenuated our findings, and limited power especially for subgroup analyses are noticeable weaknesses. In addition, the interpretation of treatment response in an observational study may need to be viewed with caution (41) . Moreover, in our analyses we pooled all data from the different hospitals, in which of course slightly different treatment regimens may have been followed. However, comparing the results of the main overall survival analyses, these did not differ if we stratified for hospital (data not shown). Moreover, all analyses based on the imputed data sets were similar to when performing the analyses using unknown categories (data not shown).
Results for breast cancer-specific, disease-free, and distant metastasis-free results were in line with those for overall survival taking into account our findings regarding ovarian cancer mortality. However, our study was underpowered, as were previously published studies, for these outcomes (13) . On the other hand, breast cancer patients in our study were young and if they were deceased this was most likely attributable to breast cancer (even though in part of the cohort this information was missing), making overall survival analyses to a large extent representative of breast cancer-specific outcomes.
This study complied with Dutch regulation and guidelines regarding secondary use of data, using coding of data and a third trusted party. This implied that we were unable to return BRCA1/2 mutation results obtained in the research setting to patients, even if they were alive and wished to be informed. Earlier analyses in one of the participating hospitals showed that 70% of the BRCA1/2 mutation carriers diagnosed after 1995 were (eventually) referred to the Clinical Genetic Center (2) .
In this cohort of young breast cancer patients (age < 50 years), an absolute 10-year overall survival difference of 10% was seen in BRCA1 and BRCA2 mutation carriers compared with noncarriers. This worse outcome for BRCA1 mutation carriers, and to a lesser extent for BRCA2, was partly attributable to differential tumor characteristics, partly explained by increased incidence of second ovarian cancers, and partly explained by response to systemic adjuvant treatment. This is in line with statements of others that worse survival in young breast cancer patients is more likely to be attributable to tumor subtype and treatment response than due to BRCA1/2 mutations (42,43). However, more detailed information on tumor subtypes may reveal more subtle differences, which we have not accounted for. The increased risk of ovarian cancer and its impact on overall survival indicates the importance of personalized strategies after breast cancer, especially for BRCA1 mutation carriers. 
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